Compared side by side
Semaglutide vs ecnoglutide: how they differ
The short answer
Both are weekly GLP-1 receptor agonists on the same receptor; ecnoglutide, from Sciwind Biosciences, carries one amino-acid change built to favour the receptor’s cAMP signal (“cAMP-biased”), plus a fatty-acid chain for a long half-life. Semaglutide is FDA-approved, as Ozempic and Wegovy; ecnoglutide was approved in China in 2026 for weight management and type 2 diabetes and isn’t FDA-approved. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial, and ecnoglutide’s 2.4 mg about 13% at 40 weeks and about 15% at 48 weeks in its phase 3 obesity trial.
Side by side
| Compared | Semaglutide | Ecnoglutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Ozempic, Wegovy | XW003, XW004, VRB-101, Ecno |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | Once-weekly GLP-1 receptor agonist, the same receptor as semaglutide, with one amino-acid change that is thought to favour the receptor's cAMP signal over the step that pulls the receptor into the cell, plus a fatty-acid chain for a long half-life. Developed by Sciwind Biosciences in China, where it was approved in 2026 for type 2 diabetes and for weight management; it is not FDA-approved. A weekly tablet form is in trials. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | Appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | Research range: 0.6–2.4 mg, starting dose 0.3 mg. Studied in research — not a recommendation. |
| How often | Weekly SubQ | Weekly |
| Half-life | ~1 week (FDA label) | ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | Used continuously, once weekly, in its trials: 40 to 48 weeks in obesity and up to 52 weeks in type 2 diabetes, with the dose doubled every 4 weeks up to the maintenance dose. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Decreased appetite, diarrhea, nausea, abdominal bloating, weakness |
- Category
- SemaglutideMetabolic & GLP-1
- EcnoglutideMetabolic & GLP-1
- Also known as
- SemaglutideOzempic, Wegovy
- EcnoglutideXW003, XW004, VRB-101, Ecno
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- EcnoglutideA weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased".
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- EcnoglutideOnce-weekly GLP-1 receptor agonist, the same receptor as semaglutide, with one amino-acid change that is thought to favour the receptor's cAMP signal over the step that pulls the receptor into the cell, plus a fatty-acid chain for a long half-life. Developed by Sciwind Biosciences in China, where it was approved in 2026 for type 2 diabetes and for weight management; it is not FDA-approved. A weekly tablet form is in trials.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- EcnoglutideAppetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- EcnoglutideResearch range: 0.6–2.4 mg, starting dose 0.3 mg. Studied in research — not a recommendation.
- How often
- SemaglutideWeekly SubQ
- EcnoglutideWeekly
- Half-life
- Semaglutide~1 week (FDA label)
- Ecnoglutide~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026)
- Route
- SemaglutideSubQ injection
- EcnoglutideSubQ injection
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- EcnoglutideUsed continuously, once weekly, in its trials: 40 to 48 weeks in obesity and up to 52 weeks in type 2 diabetes, with the dose doubled every 4 weeks up to the maintenance dose.
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- EcnoglutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- EcnoglutideDecreased appetite, diarrhea, nausea, abdominal bloating, weakness
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Ecnoglutide
- Day 1–28 · 0.3 mg A low first month
- Day 29–56 · 0.6 mg Doubling to 0.6 mg
- Day 57–336 · 1.2 mg The lowest weight-loss dose
- Day 85–336 · 1.8 mg The middle dose
- Day 85–336 · 2.4 mg The top dose
- Day 337+ A long-term medicine, not a course
Questions people ask
How long do semaglutide and ecnoglutide last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).
How often are semaglutide and ecnoglutide taken?
Semaglutide: weekly SubQ. Route: SubQ injection. Ecnoglutide: weekly. Route: SubQ injection.
How are semaglutide and ecnoglutide dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for ecnoglutide is 0.6–2.4 mg, with a 0.3 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of semaglutide and ecnoglutide?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For ecnoglutide: decreased appetite, diarrhea, nausea, abdominal bloating, weakness.